Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

By J. Mega, E. Braunwald, Satishkumar Mohanavelu, P. Burton, R. Poulter, F. Misselwitz, V. Hricák, E. Barnathan, P. Bordes, A. Witkowski and 3 more. The Lancet, 2009

663 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/9cadbc3b192d9375f0192216da16f54b05a8660b